Supplemental Annuity Collective Trust of NJ Invests $478,000 in Royalty Pharma plc (NASDAQ:RPRX)

Supplemental Annuity Collective Trust of NJ acquired a new stake in Royalty Pharma plc (NASDAQ:RPRX) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 17,000 shares of the biopharmaceutical company’s stock, valued at approximately $478,000.

A number of other large investors have also recently bought and sold shares of the business. Allworth Financial LP raised its position in shares of Royalty Pharma by 89.8% in the third quarter. Allworth Financial LP now owns 953 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 451 shares during the period. Toroso Investments LLC grew its stake in Royalty Pharma by 0.9% in the 3rd quarter. Toroso Investments LLC now owns 57,102 shares of the biopharmaceutical company’s stock valued at $1,550,000 after buying an additional 504 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Royalty Pharma by 112.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 531 shares during the period. PNC Financial Services Group Inc. lifted its position in Royalty Pharma by 10.8% during the 3rd quarter. PNC Financial Services Group Inc. now owns 5,509 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 536 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. boosted its holdings in Royalty Pharma by 8.0% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 8,210 shares of the biopharmaceutical company’s stock valued at $223,000 after acquiring an additional 607 shares during the period. 54.35% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Bank of America dropped their price objective on Royalty Pharma from $40.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, April 12th. JPMorgan Chase & Co. reduced their price objective on Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a research report on Tuesday, February 20th. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, April 11th. Finally, The Goldman Sachs Group decreased their price target on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, February 20th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Royalty Pharma currently has a consensus rating of “Buy” and a consensus target price of $46.75.

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX traded down $0.11 during midday trading on Friday, reaching $28.00. 1,358,520 shares of the company’s stock were exchanged, compared to its average volume of 2,670,692. The firm has a market capitalization of $16.73 billion, a PE ratio of 14.87 and a beta of 0.45. The company’s 50 day simple moving average is $29.65 and its two-hundred day simple moving average is $28.54. Royalty Pharma plc has a 12 month low of $25.92 and a 12 month high of $35.76. The company has a debt-to-equity ratio of 0.61, a quick ratio of 7.90 and a current ratio of 7.90.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.12. The company had revenue of $736.00 million for the quarter, compared to the consensus estimate of $702.90 million. Royalty Pharma had a return on equity of 26.93% and a net margin of 48.22%. Equities research analysts expect that Royalty Pharma plc will post 3.95 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 17th will be given a $0.21 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $0.84 annualized dividend and a yield of 3.00%. Royalty Pharma’s payout ratio is 44.44%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.